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Chronic microglial activation and resulting sustained neuroinflammatory reaction
are generally associated with neurodegeneration. Activated microglia acquires
proinflammatory cellular profile that generates oxidative burst. Their persistent activation
exacerbates inflammation, which damages healthy neurons via cytotoxic mediators,
such as superoxide radical anion and nitric oxide. In our recent study, we have shown
that benfotiamine (S-benzoylthiamine O-monophosphate) possesses anti-inflammatory
effects. Here, the effects of benfotiamine on the pro-oxidative component of activity
of LPS-stimulated BV-2 cells were investigated. The activation of microglia was
accompanied by upregulation of intracellular antioxidative defense, which was further
promoted in the presence of benfotiamine. Namely, activated microglia exposed to
non-cytotoxic doses of benfotiamine showed increased levels and activities of hydrogen
peroxide- and superoxide-removing enzymes—catalase and glutathione system, and
superoxide dismutase. In addition, benfotiamine showed the capacity to directly
scavenge superoxide radical anion. As a consequence, benfotiamine suppressed the
activation of microglia and provoked a decrease in NO and ·O− production and lipid2
peroxidation. In conclusion, benfotiamine might silence pro-oxidative activity of microglia
to alleviate/prevent oxidative damage of neighboring CNS cells.
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Introduction
Neurons are very susceptible to oxidative stress, as a result of great metabolic rate, large oxygen
consumption, relatively weak antioxidative defense, low regenerative capacity, and specific cellular
geometry (Andersen, 2004; Barnham et al., 2004). Current knowledge of neurological disorders,
from ischemia and brain injury to psychiatric disorders and neurodegenerative diseases, indicates
that pathological mechanisms involve acute or chronic activation of microglia and resulting
overproduction of reactive oxygen (ROS) and nitrogen species (RNS) by the cells (Uttara et al.,
2009; Rojo et al., 2014). These immune cells of the brain are on the constant patrol for invading
pathogens and metabolic, ischemic or traumatic brain damage (Aguzzi et al., 2013; Gertig and
Hanisch, 2014). Upon receiving the pathogen- or danger-associated signals, microglia promptly
activate, acquire amoeboid morphology, migrate toward the site of damage and release an array
of noxious, proinflammatory mediators, such as cytokines, superoxide radical anions (superoxide;
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·O−2 ), hydrogen peroxide (H2O2), and nitric oxide (NO) (Block
et al., 2007). Although microglial activation aims for removal
of potential threats from the damaged tissue, it also harms
surrounding healthy tissue via ROS production and lipid
peroxidation, which affect structural proteins and enzymes,
RNA and DNA, the integrity of membranes, and mitochondrial
membrane potential (Li et al., 2013; González et al., 2014). Apart
from this, as proliferation and pro-oxidative activity of microglia
appear to be propagated by ROS (Jekabsone et al., 2006; Mander
et al., 2006), these species potentiate microglial activity in feed-
forward manner and exacerbate inflammation (Min et al., 2004;
Barger et al., 2007; Rojo et al., 2014). Modulation and suppression
of microglia activation has been shown to alleviate symptoms
in various neurological conditions that have been related to
hyper-reactive microglia, such as brain injury (Roth et al.,
2014), multiple sclerosis (Giunti et al., 2014), Alzheimer’s disease
(Solito and Sastre, 2012), Parkinson’s disease (Van der Perren
et al., 2015), and amyotrophic lateral sclerosis (Frakes et al.,
2014). In order to bring under control oxidative burst exerted
by microglia on its surroundings in the CNS, two potential
strategies might be applied: (i) direct scavenging/detoxification
of ROS; (ii) up/down-regulation of endogenous systems for
removal/formation of reactive oxygen species (Kumar et al.,
2014; Miljkovic et al., 2015). It is noteworthy that both strategies
already offered some promising results. For instance, intracranial
application of glutathione (GSH) modulates microglia activity
and improves clinical outcomes of brain injury (Roth et al., 2014).
Similarly, a novel drug for treatment of multiple sclerosis—
dimethyl fumarate, affects ROS and RNS production bymicroglia
via upregulation of intracellular antioxidative system (Wilms
et al., 2010; Lin et al., 2011).
Benfotiamine (S-benzoylthiamine O-monophosphate) is an S-
acyl derivative of thiamine (vitamin B1) (Fujiwara, 1954) and
is easily absorbed with good bioavailability and safety profile
(Bitsch et al., 1991; Balakumar et al., 2010). Favorable effects of
benfotiamine have been already documented in the treatment
of diabetic and alcoholic neuropathies (Hammes et al., 2003;
Balakumar et al., 2010; Manzardo et al., 2013). Mechanisms of
benfotiamine action include antioxidative and anti-inflammatory
effects as documented under both, in vitro and in vivo settings
(Ceylan-Isik et al., 2006; Wu and Ren, 2006; Balakumar et al.,
2008; Schmid et al., 2008; Schupp et al., 2008; Verma et al., 2010;
Harisa, 2013), as well as in patients suffering from diabetes type II
(Stirban et al., 2006). We have recently shown that benfotiamine
attenuates microglial activation by altering cell morphology and
suppressing the production of proinflammatorymediators. These
effects were mediated via nuclear factor kappa-B (NF-κB) and
MAPK signaling, on which benfotiamine exerted direct effects
(Bozic et al., 2015).
Therefore, benfotiamine represents an off-the-shelf agent,
whose potential applications might expand to other conditions
that are related to microglia “outrage”. Here we examined the
effects of benfotiamine on pro-oxidative activity of activated
BV-2 microglia cells. The focus was on the main components
of the endogenous antioxidative system: catalase (CAT),
cytoplasmic and mitochondrial superoxide dismutases (SOD1
and SOD2, respectively), along with total glutathione and
enzymes involved in its metabolism, GSH peroxidase (GPx) and
reductase (GR).
Materials and Methods
Cell Culture and Treatment
BV-2 cell line was derived from primary microglial cells of
C57BL/6 newborn mice infected with v-raf/v-myc retrovirus
(Blasi et al., 1990). These cells express functional NADPH oxidase
(Henn et al., 2009). They were a kind gift from Dr. Alba
Minelli from the University of Perugia, Italy. BV-2 microglia was
cultured in RPMI 1640 medium (GE Healthcare Life Sciences,
Freiburg, Germany) containing 10% heat-inactivated fetal bovine
serum (FBS, PAALaboratories GmbH, Pasching, Austria) and 1%
penicillin/streptomycin (Invitrogen Co, Carlsbad, CA, USA) at
37◦C in a humidified incubator with 5% CO2. Upon confluence,
cells were collected with 0.1% trypsin-EDTA (PAA Laboratories
GmbH, Pasching, Austria), centrifuged (500 × g for 5min) and
seeded in culture dishes, depending on the experiment. Cell
were exposed to benfotiamine (50, 100, 250µM; Sigma-Aldrich
Labware, Munich, Germany) 30min prior to stimulation with
1µg/ml LPS (Escherichia coli serotype 026:B6; Sigma-Aldrich
Labware, Munich, Germany) for 24 h or as indicated. Treatment
with inhibitor of inducible NO synthase (iNOS), Nω-Nitro-L-
arginine methyl ester hydrochloride (L-NAME) was performed
1 h before BV-2 cells were incubated with LPS for 24 h.
Cell Viability Assay
For MTT test, cells were grown in 96-well plates (1 × 104
cells/well), exposed to benfotiamine and LPS for 24 h,
as previously described (Bozic et al., 2015). The test
based on a reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to formazan is an indicator
of total mitochondrial status of viable cells. Cells were incubated
with MTT solution (5mg/ml) for 30min at 37◦C. Purple crystals
of formazan were dissolved in DMSO and absorbance was
measured at 492 nm with a microplate reader (LKB 5060-006,
Vienna, Austria). The results are expressed as % of mean optical
density (OD 492 nm) relative to control ± SEM, from three
independent determinations performed in triplicate.
Flow Cytometric Analysis
Cells were seeded in 6-well plates (3 × 105 cells/well)
and treated as described. They were detached with 0.1%
trypsin-EDTA, centrifuged at 750 × g for 3min and washed
twice with phosphate buffered saline (PBS). Subsequently, the
cells were stained with FITC-conjugated anti-mouse CD40
antibody or isotype control (1:200, BD Pharmingen) for
1 h at 4◦C. BV-2 microglia was spun down, rinsed twice
with PBS and analyzed with CyFlow R© Space Partec (Partec
GmbH, Munster, Germany) using PartecFloMax R©software
(Partec GmbH, Munster, Germany). Minimum of 10,000 cells
were analyzed and results are presented as % (dot plots) and
number (graph) of cells expressing CD40.
For determination of apoptotic and necrotic cell death, cells
were incubated with annexin V FITC and propidium iodide
(Molecular Probes, Invitrogen, Carlsbad, CA) for 15min in
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the dark at room temperature (RT). Annexin V binds to
phosphatidylserine that is exposed on the outer leaflet of plasma
membrane of apoptotic (and at least in some cases necrotic)
cells. Propidium iodide is a DNA intercalating agent that can
enter only necrotic cells. Thus, cells positive only for annexin
V were identified as apoptotic, whereas cells that were positive
for propidium iodide and annexin V were recognized as necrotic.
The reaction was stopped by centrifuging cells and resuspending
them in Annexin Binding Buffer. Analysis was performed at
CyFlow R© Space Partec using PartecFloMax R© software.
Radical Generating Systems
Radical-generating systems were prepared as described
previously (Miljkovic et al., 2015). The ability of benfotiamine
to scavenge hydroxyl radical (·OH) was tested using the Fenton
system (Fe2+ + H2O2 → Fe3+ + OH− + ·OH). The Fenton
reaction was performed in PBS (pH = 7.4) by combining
1mM of H2O2 (Renal, Budapest, Hungary) and 0.2mM of
FeSO4(Merck, Darmstadt, Germany). Spin trap DEPMPO
(5-diethoxyphosphoryl-5-methyl-1-pyrroline-N-oxide; Enzo
Life Sciences International, Plymouth Meeting, PA, USA; 10mM
final concentration) was added prior to H2O2. The time period
between the initiation of reaction and EPR measurements was
2min. Benfotiamine was supplemented before the initiation of
reaction at the final concentration of 1mM.
Superoxide was generated using ·O−2 thermal source SOTS-1
(Cayman Chemicals, Ann Arbor, MI, USA). Immediately prior to
the start of any experiment the SOTS-1 was dissolved in DMSO,
and was further supplemented to PBS solution containing
DEPMPO (10mM) and DTPA (1mM; chelating agent, which is
added in order to suppress the redox activity of transition metals
impurities in ·OH-generating Haber-Weiss reaction), to a final
concentration of 0.2mM. This system was incubated for 5min at
37◦C. The time period between the end of incubation and EPR
measurements was 2min.
EPR Spectroscopy
EPR measurements were performed on X-band (9.57 GHz)
Varian E104-A EPR spectrometer, using EW software (Scientific
Software, Bloomington, IL, US). Settings were: 10mW,
microwave power; 2 G, modulation amplitude; 3410 G, field
center; 200 G, scan range; 4min, scanning time; 100 kHz,
modulation frequency; 32ms, time constant. Samples were
drawn into gas-permeable Teflon tubes (internal diameter
0.6mm; wall thickness 0.025mm; Zeus industries, Raritan, NJ,
USA) to maintain constant oxygen level in the sample, Teflon
tubes were placed in quartz capillaries. DEPMPO reacts with
·OH and ·O−2 producing DEPMPO/OH and DEPMPO/OOH
adducts, respectively. Signal intensities were determined using
spectral simulations, which were conducted using WINEPR
SimFonia computer program (Bruker Analytische Messtechnik
GmbH, Darmstadt, Germany). Simulation parameters were: (i)
DEPMPO/OH adduct: aN = 13.64 G; aH = 12.78 G; aP = 46.7
G; (ii) DEPMPO/OOH adduct: isomer I (50%): aN = 13.4 G,
aHβ = 11.9 G, aHγ (1H)= 0.8 G, aHγ (6H)= 0.43 G, aP= 52.5
G; isomer II (50%): aN = 13.2 G, aHβ = 10.3 G, aHγ (1H) =
0.9 G, aHγ (6H) = 0.43 G, aP = 48.5 G. Antioxidative activity
(AA) was calculated using the following formula: (I0 - Ix)/I0,
where I0 and Ix are the intensities of EPR spectra obtained in
control and samples with benfotiamine. Maximal AA value is 1.
EC50-value (mM) is the effective concentration at benfotiamine
provoked 50% decrease in DEPMPO/OOH yield, obtained by
interpolation from linear regression analysis. Each experiment
was performed in triplicate. In addition, the rate constant for
benfotiamine reaction with superoxide was calculated using
previously described method and rate constant for the reaction
between DEPMPO and superoxide (approximately 4 M−1 s−1).
Quantitative Real-time PCR
BV-2 microglia was plated (6-well plates, 3 × 105 cells/well)
and incubated with benfotiamine and LPS. Four hours after
the onset of LPS stimulation, cells were collected for total
RNA isolation in TRIzol reagent (Invitrogen, Carlsbad, CA,
USA). The RNA content was quantified spectrophotometrically
and the purity was evaluated by running RNA samples on
agarose gels. Reverse transcription was conducted with 1µg
of RNA, with High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA). ABI Prism 7000
Sequence Detection System (Applied Biosystems, Foster City,
CA, USA) was used for real-time PCR analysis, with SYBR
Green PCR Master Mix (Applied Biosystems, Foster City, CA,
USA) and specific primers for CAT, SOD2 and GPx (sequences
and annealing temperatures given in Table 1, Invitrogen,
Carlsbad, CA, USA). Relative expression of target genes was
evaluated using the 2−11CTmethod, with β-actin as internal
control.
Western Blot
Western blot analysis was performed as previously described
(Bozic et al., 2015). Briefly, after treatment cells were lysed,
samples were centrifuged and protein content was determined.
Equal amounts of total cellular proteins were loaded per
lane of 10% (for analysis of SOD2 and GPx) and 7.5% (for
analysis of CAT and GR) polyacrylamide gels. Proteins were
resolved at constant voltage (100–120V) and transferred to
polyvinylidene fluoride (PVDF) support membrane (Roche,
Penzberg, Germany). Support membranes were blocked with
the blocking solution (5% BSA dissolved in TBST (20mM
Tris, pH 7.6, 136mM NaCl, 0.1% Tween 20) for 1 h at RT to
eliminate unspecific binding. Membranes were incubated
overnight with primary antibodies (Table 2), washed 3
times for 10min with TBST and incubated with secondary
antibodies for 1 h at RT. Chemiluminescence was used to
visualize antibody binding. Protein bands were analyzed using
ImageQuant 5.2 software, by determining optical density of
the band and normalizing it to the optical density of β-actin
from the same lane. Results are expressed as mean relative
target protein/β-actin abundance ± SEM, from three separate
determinations.
Determination of Parameters Involved in Cell
Oxidative State
BV-2 cells were plated (6-well plates, 3 × 105 cells/well) and
stimulated for 24 h as described. Cells were rinsed with ice
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TABLE 1 | List of primers used for Real-time PCR.
Target gene Forward primer Reverse primer Size (bp) Annealing T (◦C)
CAT AGCGACCAGATGAAGCAGTG TCCGCTCTCTGTCAAAGTGTG 181 64
MnSOD CAGACCTGCCTTACGACTATGG CTCGGTGGCGTTGAGATTGTT 113 64
GPx AGTCCACCGTGTATGCCTTCT GAGACGCGACATTCTCAATGA 105 64
Actin GGGCTATGCTCTCCCTCAC GATGTCACGCACGATTTCC 136 63
TABLE 2 | List of primary antibodies used for flow cytometry (FC) and
western blot (WB).
Antigen Source Dilution Company
CD40 mouse 1:200 (FC) BD Pharmingen
CAT Rabbit 1:5000 (WB) Abcam
GPx Rabbit 1:5000 (WB) Abcam
MnSOD Rabbit 1:5000 (WB) Abcam
GR Rabbit 1:5000 (WB) Abcam
cold PBS and collected with a cell scraper. Cells were lysed
by sonication and centrifuged at 15,000 × g for 5min, at
4◦C. Supernatants were collected and used for determination of
·O−2 , malondialdehyde (MDA) and total glutathione (reduced +
oxidized) and activity of enzymes involved in antioxidative
defense, SOD2, CAT, GPx, and GR. The protein content was
determined by the method of Lowry using bovine serum albumin
as standard (Lowry et al., 1951).
Measurement of NO Production
BV-2 microglia was seeded in 24-well plates (5 × 104 cells/well),
and treated as described. Culture medium was collected,
deproteinized and concentration of NO was evaluated by
measuring nitrite and nitrate concentrations. Griess method was
used to determine the nitrite content. Griess reagent was made
of 1.5% sulfanilamide (Sigma-Aldrich, Munich, Germany) in 1M
HCl and 0.15% N-(1-naphthyl) ethylendiamine dihydrochloride
(Fluka, Buchs, Switzerland) in distilled water. Nitrates were
first transformed into nitrites by cadmium reduction (Navarro-
Gonzálvez et al., 1998). Concentration of nitrites released in the
medium was determined from the standard curve generated with
known concentrations of sodium nitrite (Mallinckrodt Chemical
Works—St. Louis, MO, USA). Results are expressed as mean
concentration of nitrites (µM) ± SEM, from three separate
determinations.
Superoxide Anion Radical
Concentration of ·O−2 was evaluated with the method based on
the reduction of nitroblue-tetrazolium—NBT (Sigma-Aldrich—
Sr. Louis, USA) tomonoformazan by ·O−2 in the alkaline nitrogen
saturated medium. The product of this reaction is yellow and was
measured spectrophotometrically at 550 nm (Auclair and Voisin,
1985). The results are expressed as mean reduced NBT (relative
to control—100%) ± SEM, from three separate determinations
performed in duplicate.
Malondialdehyde (MDA)
Spectrophotometric method of Villacara et al. (1989) was used
for determination of MDA concentration. MDA gives a red
product after incubation with thiobarbituric acid (TBA) reagent
(15% trichloroacetic acid and 0.375% TBA, water solution,
Merck—Darmstadt, Germany), at 95◦C and pH 3.5. Absorbance
was measured at 532 nm. The results were expressed as mean
MDA concentration (nmol/ml) ± SEM, from three separate
determinations, performed in duplicate.
Total Glutathione
DTNB-GSSG reductase recycling assay was used for
determination of total glutathione content. The rate of formation
of 5-thio-2-nitrobenzoic acid (TNBA), corresponding to
total concentration of glutathione, was measured at 412 nm
(Anderson, 1986). The results are expressed as mean
concentration of glutathione (nmol/ml) ± SEM, from three
separate measurements performed in duplicate.
Superoxide Dismutase Activity
Total SOD activity, which combines the activity of two SOD
isoforms, cytoplasmic SOD1 (Cu,ZnSOD) and mitochondrial
SOD2 (MnSOD), was evaluated by the epinephrine method.
Activity of SOD (EC 1.15.1.1.) was assayed as inhibition of
spontaneous autooxidation of epinephrine (Sigma-Aldrich—St.
Louis, USA), by measuring absorbance at 480 nm. The kinetics
of enzyme activity was followed in a carbonate buffer (50mM,
pH 10.2, containing 0.1mM EDTA, Serva, Feinbiochemica—
Heidelberg, New York), after the addition of 10mM epinephrine
and 5mM KCN for MnSOD isoform (Sun and Zigman, 1978).
The results were expressed as units per milligram of protein. One
unit is defined as an amount of protein (enzyme) required for
50% of auto oxidation of epinephrine.
Catalase Activity
CAT activity was determined by a method based on
spectrophometric determination (405 nm) of colored complex
formed between ammonium molibdate and H2O2 (Góth, 1991).
Unit of CAT activity is defined as the amount of H2O2 reduced
per minute (µmol H2O2/min). Data are expressed as mean
CAT activity (units/mg protein) ± SEM; from three separate
determinations performed in duplicate.
Glutathione Peroxidase Activity
Activity of GPx is measured by indirect spectrophotometric
determination of the GPx -mediated NADPH consumption
(340 nm), as previously described (Maral et al., 1977; Djukic et al.,
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2012). The results are expressed as miliunits per milligram of
protein.
Glutathione Reductase Activity
Method for determining the activity of the GR is based
on the ability of GR to catalyze the reduction of GSSG to
GSH by the oxidation of the coenzyme NADPH to NADP+
(Freifelder, 1976). In the reaction as standard we used 100mmol
NAD+. The unit of enzyme activity is defined as number of
micromols of NADPH oxidized per minute (µmol NADPH).
The results were expressed as mean GR activity (mU/mg
protein) ± SEM, from n separate determinations performed in
duplicate.
Measurement of Intracellular ATP
Intracellular ATP was extracted from BV-2 cells with boiling
water, as described previously (Yang et al., 2002). Medium was
removed and boiling water was added to cells, which were
quickly scraped to obtain cell suspensions. Cell suspensions were
boiled for 10min and centrifuged at 12,000 × g for 5min,
at 4◦C. Supernatants were used for immediate determination
of ATP by bioluminescent assay kit (Sigma Aldrich, St. Louis,
USA), according to the manufacturer’s instruction. Samples were
incubated with the assay mix containing luciferin and luciferase
and the luminescence intensity proportional to ATP content was
measured with luminometer (CHAMELEON™V, Hidex, Turku,
Finland). ATP standard curve was constructed for determination
of ATP concentration in samples. Results are expressed as nmols
of ATP permg of protein.
Statistical Analysis
Results are expressed as mean values± SEM. To assess statistical
significance in all experiments, experiments were performed in
duplicate or triplicate determinations using three separate cell
preparations. Statistical analysis was completed with GraphPad
Prism software. Data were analyzed using One-Way ANOVA
(except data for ATP, which were analyzed using Two-Way
ANOVA) with Bonferroni post-hoc analysis. Values of p < 0.05
were considered statistically significant.
Results
Benfotiamine Suppresses LPS-induced CD40
Expression in BV-2 Cells
CD40 expression by BV-2 cells was used as an indicator of
microglial activation (Qin et al., 2005). In control BV-2 cells
constitutive expression of surface CD40 was low, and only about
100 per 10,000 cells analyzed by FACS expressed CD40 receptor
(Figure 1). Treatment with LPS (1µg/ml) for 24 h upregulated
the expression of CD40 by approximately 40% (4000 cells were
positive for CD40). Pretreatment of BV-2 cells with 100 and
FIGURE 1 | FACS analysis of CD40 expression in BV-2 cells. Expression of immunoregulatory receptor CD40 was analyzed with FACS and
representative dot plots are shown for control (C), group treated with LPS (LPS) for 24 h, and groups pretreated with benfotiamine in doses of 50, 100,
and 250µM and then treated with LPS for 24 h [LPS + B (50µM), LPS + B (100µM), and LPS + B (250µM)]. Statistical analysis was performed
and mean values from three independent experiments are presented on the graph, for control cultures (white bar), LPS treated cells (black bar) and
groups pretreated with different doses of benfotiamine and then stimulated with LPS (gray bars). ***p < 0.001 compared with control group,
###p < 0.001 compared with LPS treated group.
Frontiers in Cellular Neuroscience | www.frontiersin.org 5 September 2015 | Volume 9 | Article 351
Bozic et al. Benfotiamine alleviates oxidative damage
FIGURE 2 | Effect of benfotiamine on viability and apoptotic and necrotic cell death of LPS (1 µg/ml) stimulated BV-2 cells. Cell viability was evaluated
with MTT assay, 24 h after treatment with LPS (A). FACS analysis of apoptotic and necrotic cell death was performed with FITC labeled annexin V and propidium
iodide (B). Apoptotic cells were labeled with annexin V, whereas necrotic cells were positive for both annexin V and propidium iodide. Percentage of apoptotic (C) and
necrotic (D) cells was determined from three independent cell preparations. ***p < 0.001 compared with control group. Activation of caspase—3 was assessed with
western blotting for active caspase—3 fragment (E). Representative blot from three independent experiments is shown. Band intensity was analyzed, compared to
β-actin of the same lane and results are expressed in arbitrary units.
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FIGURE 3 | Effect of benfotiamine on levels of NO, ·O−
2
and MDA in BV-2 cells stimulated with LPS (1 µg/ml) for 24h. (A) NO production was measured
with Griess assay 24 h after LPS treatment and results are expressed as mean values ± SEM (n = 3). Intracellular concentrations of ·O−2 (B) and MDA (C) were
measured in three independent cell preparations of BV-2 cells after 24 h treatment with LPS. (D) EPR signals of DEPMPO/OH adducts in the Fenton system without (a)
or with (b) benfotiamine (1mM); (E) Characteristic EPR signals of DEPMPO/OOH generated by SOTS-1 without (a) or with (b) benfotiamine (0.5mM) (F) Antioxidative
activity of benfotiamine against ·O−2 . ***p < 0.001 compared with control group,
#p < 0.05, ##p < 0.01, ###p < 0.001 compared with LPS treated group.
250µM benfotiamine significantly decreased the number of
CD40 expressing cells to 3000 (p < 0.001). The results indicate
that benfotiamine influence on activated BV-2 cells involves
expression of CD40.
Benfotiamine Does Not Affect Viability of
LPS-activated BV-2 Cells
Effect of benfotiamine pretreatment on BV-2 cells’ state was
determined using MTT assay and Annexin V/propidium
iodide FACS analysis after 24 h treatment with LPS (1µg/ml.
Benfotiamine did not change total mitochondrial activity of
LPS-stimulated BV-2 cells, as deduced from stable MTT
values (Figure 2A). Annexin V/PI FACS analysis (Figure 2B)
demonstrated, however, that LPS caused modest increase in
the proportion of apoptotic (about 11% of cells, Figures 2B,C)
and necrotic (approximately 10% of cells, Figures 2B,D) cells in
cultures. Importantly, benfotiamine did not significantly affect
the viability of LPS-stimulated cells (Figure 2). The finding was
further substantiated by immunoblot analysis of active fragment
of caspase-3. A slight increase in caspase-3 expression was
observed in LPS stimulated cells, whereas benfotiamine showed
no such effects (Figure 2E). Furthermore, the treatments did not
affect cell proliferation (Figure S2).
Benfotiamine Decreases Production of NO, ·O−2 ,
and MDA
Production of NO and intracellular content of superoxide
anions (·O−2 ) and MDA were determined as they represent
critical indicators of oxidative stress. LPS stimulation (1µg/ml,
24 h) resulted in several fold increase of levels of NO, ·O−2
and MDA (Figures 3A–C). Benfotiamine pretreatment (30min
prior to LPS) suppressed NO release (Figure 3A) in a dose-
dependent manner (p < 0.001). Concentration of ·O−2 ,
was increased 2.5-fold with LPS stimulation (Figure 3B). This
was suppressed by pretreatment with benfotiamine, which, at
250µM dose returned ·O−2 content to control levels (p <
0.001). Furthermore, benfotiamine substantially downgraded
LPS-induced lipid peroxidation (Figure 3C) at all examined
doses. In the presence of benfotiamine the yield of DEPMPO/OH
adduct was slightly increased (about 10%) compared to control
system (Figure 3D). This implies a modest pro-oxidative activity
of benfotiamine, probably via Fe3+ reduction. On the other
hand, benfotiamine significantly affected generation of ·O−2
(Figure 3E) at concentrations corresponding to those applied
in experiments on microglia (Figure 3F). It was estimated that
the rate constant for the reaction between benfotiamine and
·O−2 was 68 ± 19 M
−1 s−1. These data together imply that
benfotiamine exhibits significant antioxidative activity in BV-2
cells.
Benfotiamine Modulates Expression of Enzymes
Involved in Antioxidative Defense
To shed more light on possible mechanism of antioxidative
actions of benfotiamine, we further determined gene expression
levels for SOD2, CAT, and GPx by qRT-PCR. These enzymes
constitute essential part of antioxidative cellular defense, since
SOD2 dismutates ·O−2 to H2O2, while CAT and GPx convert
H2O2 to water. BV-2 cells were pretreated with benfotiamine
and the mRNA content was determined 4 h after LPS stimulation
(Figure 4). SOD2 gene expression was promoted three-fold by
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FIGURE 4 | Effect of benfotiamine on gene expression of antioxidative
enzymes in LPS stimulated BV-2 cells. Expression of MnSOD (A), CAT (B),
and GPx (C) was evaluated with RT PCR and expressed relative to the
expression of β-actin mRNA. BV-2 cells were pretreated with different doses of
benfotiamine (50, 100, and 250µM) for 30min, stimulated with LPS for 4 h
and then harvested for mRNA isolation. Three independent experiments were
performed and statistical significance was marked as **p < 0.01 compared
with control group, ##p < 0.01, ###p < 0.001 compared with LPS treated
group.
LPS, while benfotiamine, at its highest concentration, induced
even higher increase (p < 0.01, Figure 4A). On the other
hand, while LPS alone did not affect expression of CAT gene,
250µM benfotiamine induced 2-fold increase in the CAT-
mRNA abundance compared to LPS group (p < 0.001,
Figure 4B). Finally, no significant effects on GPx-mRNA were
observed (Figure 4C). Taken together, these results suggest that
antioxidative actions of benfotiamine may be partly mediated
via induction of antioxidative enzyme genes, including SOD2
and CAT.
Benfotiamine Upregulates Protein Expression of
Antioxidative Defense Enzymes
Expression of antioxidative enzymes SOD2, CAT, GPx, and GR
was further evaluated at the protein level byWestern blot analysis
(Figure 5). Among the antioxidative enzymes tested, LPS affected
only protein expression of CAT (Figure 5B). Benfotiamine,
however, induced significant effects on SOD2 (p < 0.001,
Figure 5A) and CAT protein expression (p < 0.05, Figure 5B).
No changes in the protein expression of GPx and GR were
observed (Figures 5C,D, respectively).
Benfotiamine Enhances the Activity of
Antioxidative Enzymes and Increases Glutathione
Content in BV-2 Cells
Antioxidative potential of benfotiamine in BV-2 cells was
further analyzed in terms of antioxidative enzymes activity
and intracellular content of total glutathione, main non-
enzymatic antioxidant in microglia. The cells were pretreated
with benfotiamine in 50, 100, and 250µM dose for 30min
and then stimulated with LPS (1µg/ml) for 24 h. Activity
of MnSOD increased upon LPS stimulation, whereas it was
not affected by benfotiamine (Figure 6A). On the contrary,
activity of Cu,ZnSOD was not affected by LPS while it was
doubled by pretreatment with 250µM benfotiamine (p < 0.01,
Figure 6B). CAT activity (Figure 6C) was substantially inhibited
in cells treated with LPS (from 10 U/mg in control cells to
4 U/mg in LPS treated group, p < 0.001). Benfotiamine
induced dose-dependent increase reaching the control CAT
activity at the highest concentration (approximately 9 U/mg,
p < 0.001). Benfotiamine had no effect on CAT activity
in non-stimulated cells (Figure S1A). The inhibition of iNOS
ameliorated the inhibitory effects of LPS stimulation on CAT
activity (Figure S1B). GPx activity was not affected by LPS
stimulation nor benfotiamine treatment (Figure 6D). Activity
of GR decreased after LPS stimulation and slightly increased
after the benfotiamine pretreatments (Figure 6E). Finally, total
glutathione content was substantially decreased in the microglial
cells stimulated with LPS (Figure 6F). This was annihilated by
benfotiamine which provoked a significant increase compared to
control values.
Benfotiamine Increases Intracellular ATP Content
Intracellular ATP level was measured in BV-2 cells at three time
points (1, 4, and 24 h) after LPS stimulation (Figure 7). In cells
treated with LPS, intracellular ATP content was higher compared
to control levels 4 h after the treatment and remained higher
24 h later. Pretreatment with 250µM benfotiamine induced
an increase of ATP content at 1 h after the LPS stimulation.
Increased level remained increased 24 h later. The effects of LPS
and benfotiamine peaked at 4 h.
Discussion
Activated microglia undergoes transformation which involves
morphological changes, induction of surface markers, increased
production of various proinflammatory cytokines and
acquisition of cellular profile that generates oxidative burst
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FIGURE 5 | Effect of benfotiamine on protein expression of antioxidative enzymes in LPS treated BV-2 cells. Protein expression of MnSOD (A), CAT (B),
GPx (C), and GR (D) was evaluated with western blotting, 24 h after LPS treatment. Representative blots from three independent experiments are shown. Protein
bands were analyzed with Image Quant 5.2 software, compared to β-actin of the same lane and results in graphs are expressed as percentage of control group.
*P < 0.05 compared with control group, #p < 0.05, ###p < 0.001 compared with LPS treated group.
(Block and Hong, 2005; Bordt and Polster, 2014). Pertinent to
the latter, activated microglia releases ROS and RNS, such as
·O−2 and NO (as shown here) via NADPH oxidase activity (on
membrane) and inducible NO synthase—iNOS (intracellular),
respectively (Dringen, 2005). Such setup limits the production
of highly dangerous peroxynitrite (·O−2 + NO → ONOO
−)
in the extracellular fluid, thus targeting outer targets (such
as pathogens), but simultaneously protecting microglia from
self-inflicting damage. Self-protection of activated microglia is
also effectuated by significant induction of intrinsic antioxidative
system. Our data confirm increased expression of CAT and SOD2
and increased SOD2 activity in LPS activated microglia which
is in agreement with previously reported data (Dringen, 2005).
Increased expression of CAT contribute to the efficient removal
of H2O2, which permeates cell membrane, after being produced
by extracellular dismutation of ·O−2 (Gao et al., 2003). The
observed increase in the level of mRNA and enzymatic activity of
SOD2 is most likely related to increased mitochondrial activity
(and number) in activated microglia (Park et al., 2013). Increased
demands for energy production in LPS activated microglia is met
through enhanced ATP synthesis which requires the acceleration
of electron transfer chain. Under such conditions, electron leak
and ·O−2 generation in mitochondria are promoted and this is
mitigated through higher activity of SOD2 (Bordt and Polster,
2014). Increased SOD1 activity (this SOD is mainly located in
the cytosol), might be a response to increased cyclooxygenase-2
activity in activated microglia (Siomek, 2012). This enzyme has
·O−2 as a by-product (Marnett et al., 1999). Interestingly, CAT
showed increased levels but lower activities in activatedmicroglia
compared to resting cells. This implies inhibition. Pertinent to
this, CAT is reversibly inhibited by NO (Brown, 1995), whereas
GR is inhibited by ONOO− (Francescutti et al., 1996).
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FIGURE 6 | Effect of benfotiamine on activity of antioxidative enzymes and total glutathione content in LPS treated BV-2 cells. Activity of MnSOD (A),
Cu,ZnSOD (B), CAT (C), GPx (D), GR (E), and total glutathione content (F) was analyzed in BV-2 cells following LPS treatment for 24 h. The results of activity of
antioxidative enzymes are expressed as mean specific activities (U/mg) ± SEM from three independent cell preparations. *p < 0.05, ***p < 0.001 compared with
control group, #p < 0.05, ##p < 0.01, ###p < 0.001 compared with LPS treated group.
Benfotiamine modulates oxidative activity but does not
kill microglia, which is a preferred way of action for drugs
targeting hyper-active microglia in neurological conditions
(Uttara et al., 2009; Luo et al., 2010; Roth et al., 2014).
Thiamine, a benfotiamine metabolite, enters the CNS, as shown
using high performance liquid chromatography which has
demonstrated higher thiamine concentration in the brain after
oral administration of benfotiamine in mice. Beneficial effects
of benfotiamine on mouse model of Alzheimer’s disease have
been attributed to both benfotiamine and thiamine (Pan et al.,
2010). Benfotiamine decreases the expression of CD40, a protein
that determines antigen presenting ability of microglia and
activation of NF-κB signaling (Kim et al., 2002; Kraft and
Harry, 2011; Morgan and Liu, 2011). CD40 has an important
role in neuroinflammatory diseases and abnormal expression
of CD40 and its ligand CD154 has been shown in Alzheimer’s
disease (Calingasan et al., 2002; Giunta et al., 2010), multiple
sclerosis (Gerritse et al., 1996), and HIV-1 associated dementia
(D’Aversa et al., 2002). Considering that activation of CD40
receptor in microglia leads to expression of iNOS and production
of TNF-α (Jana et al., 2001, 2002) and other proinflammatory
molecules (Chen et al., 2006), benfotiamine’s ability to suppress
CD40 expression can alleviate inflammation in neurological
disorders. Benfotiamine also exhibits strong antioxidative
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abilities and suppresses oxidative burst. It decreased NO and
·O−2 production and lipid peroxidation of microglial membrane.
The potency of benfotiamine to inhibit lipid peroxidation
and ·O−2 overproduction has been observed previously in
murine kidney exposed to cisplatin and endothelium exposed
to nicotine (Balakumar et al., 2008; Harisa, 2013). Benfotiamine
induced fall in NO production is most likely caused by
down-regulation of iNOS expression due to suppressed NFκB
signaling in benfotiamine-treated microglia (Bozic et al., 2015).
The effects on ·O−2 production might be based upon the
capacity of benfotiamine to directly scavenge this radical,
but also on its inhibitory effects on the activity of NF-
κB, which is involved in the expression of NADPH oxidase
(Morgan and Liu, 2011; Siomek, 2012). However, the most
important finding here is that benfotiamine upregulated the
intracellular antioxidative system, thus increasing the capacity
of activated microglia to buffer the excessive production
of ROS.
Namely, in the presence of benfotiamine, microglial cells
showed increased levels of CAT and SOD2 mRNA, increased
amounts of CAT and SOD2, and increased activity of CAT,
GR, and SOD1. Benfotiamine-provoked increase of CAT activity
showed dose-dependency. The effect is reciprocally proportional
to the level of NO production. Hence, increased CAT activity
can be attributed to benfotiamine-provoked decrease in the
production of NO (CAT inhibitor), as well as to the stimulation
of CAT expression. Of note, in the previous report we have
applied a less sensitive Griess protocol (no NO−3 reduction)
which allowed for benfotiamine-provoked suppression of NO
to be observed, but dose-dependency was unnoticed (Bozic
et al., 2015). The level of GR was not significantly increased in
benfotiamine-treated cells, but its activity was increased. This
implies that benfotiamine ameliorated the inhibition of GR,
which is provoked by NO derivative—ONOO−. The production
of both, NO and ONOO− in activated microglia are based
on iNOS activity (Kumar et al., 2014; Bozic et al., 2015). It
is important to point out that NO and ROS production are
intertwined. For example, H2O2 activates NF-κB activity and
hence promotes the expression of iNOS (Andrades et al., 2011).
It appears that benfotiamine might initiate a feedback loop
that has the silencing of pro-oxidative activity of activated
microglia as a result. In brief, benfotiamine provokes an increase
in the level of H2O2-removing enzyme—CAT, which should
result in lower NFκB activity and iNOS levels, as we reported
previously (Bozic et al., 2015). This further leads to lower NO
levels, and to de-inhibition of CAT. This is implied by the
fact that iNOS inhibition by L-NAME led to increased CAT
activity in LPS stimulated cells. Of note, peroxynitrite irreversibly
inhibits GR, which most likely accounts for the modest effects of
benfotiamine on this enzyme as compared to the effects on CAT
activity. Finally, this loop might be involved in benfotiamine-
provoked suppression of microglia activation (lower CD40,
proinflammatory mediators, such as TNF-α and IL-6), since it is
known that ROS can amplify microglia inflammatory response
(Mander et al., 2006).
Increased SOD2 expression and ATP levels imply that
benfotiamine promotes mitochondrial activity/number. One
FIGURE 7 | Effect of benfotiamine on intracellular ATP content of
LPS stimulated BV-2 cells. Concentration of ATP were determined in
control groups (white bars), cells treated with LPS (black bars) and cells
pre-treated with 250µM benfotiamine and then stimulated with LPS for 1,
4, and 24 h (gray bars). The results are expressed in nmol permg of
protein and represent mean values from three independent experiments ±
SEM. The groups not sharing a common letter are significantly different
(p < 0.05).
potential mechanism is that benfotiamine activates some
xenobiotic-like response. The removal of xenobiotics requires
energy, and they have been shown to promote expression of
SOD2 (Curtis et al., 2007). In addition, benfotiamine upregulated
glutathione system. The total glutathione was increased 2- to 3-
fold in activated microglia exposed to benfotiamine. This major
change may only come from de novo synthesis of glutathione (Lu,
2009). Such response is common in handling xenobiotics and
reactive molecules in CNS (Valdovinos-Flores and Gonsebatt,
2012; Zhang et al., 2013). Benfotiamine actions fall under a
relatively novel strategy in antioxidative therapy which employs
hormesis i.e., exposure to one stressor increases resistance to
another stressor (Gems and Partridge, 2008). Namely, drugs,
such as dimethyl fumarate or ethyl pyruvate (Wilms et al.,
2010; Miljkovic et al., 2015), or natural products, such as
polyphenols and other mildly stressful compounds (Talalay et al.,
2003; Moskaug et al., 2005) activate antioxidative system, which
then protects the cell from oxidative stress that is inflicted
by other sources/processes. In the present case, benfotiamine-
mediated stimulation of antioxidative system is more important
for increasing the capacity of microglia to buffer oxidative burst
than for protecting microglia per se. In conditions where no
real threat (such as infection agents) is present, and microglia
enters hyper-reactive state as a side-reaction to some pathological
processes, benfotiamine might silence pro-oxidative activity of
microglia to alleviate/prevent oxidative damage on neighboring
CNS cells.
Our results open the possibility for benfotiamine application
in neurodegenerative conditions which show hyper-reactive
microglia, such as Alzheimer’s, Parkinson’s disease, amyotrophic
lateral sclerosis or multiple sclerosis. Further research on animal
model studies are warrant in order to evaluate benfotiamine
capacity to mitigate the microglial component of pathology of
neurological diseases.
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Figure S1 | CAT activity—effect of benfotiamine in basal conditions and
effect of iNOS inhibitor (L-NAME). Activity of CAT was determined 24 h after
treatment with benfotiamine (50, 100 and 250µM) in the absence of LPS
stimulation (A). CAT activity was examined in BV-2 cells treated with L-NAME
(500µM) for 1 h and then stimulated with LPS for 24 h (B). The results are
expressed as mean specific activities (U/mg) ± SEM from three independent cell
preparations. ∗∗∗p < 0.001 compared with control group, ###p < 0.001
compared with LPS treated group.
Figure S2 | Effect of benfotiamine and LPS treatment on BV-2 cell
proliferation. BV-2 cells were treated with benfotiamine (250µM), LPS
(1µg/ml) or their combination for 24 h, stained with Ki-67 antibody and
analyzed with FACS. Representative dot plots are shown. Statistical analysis
was performed and mean values from three independent experiments are
presented on the graph.
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